| review article | Q7318358 |
| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2007.08.027 |
| P698 | PubMed publication ID | 17928109 |
| P50 | author | Leonard Leibovici | Q28037183 |
| Mical Paul | Q28037206 | ||
| Abigail Fraser | Q37384225 | ||
| Camilo J Acosta | Q91122338 | ||
| Elad Goldberg | Q114778573 | ||
| P2860 | cites work | A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial | Q24811133 |
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Typhoid fever | Q28216285 | ||
| Vaccines for preventing typhoid fever. | Q30868028 | ||
| Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine | Q33248480 | ||
| The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children | Q33944000 | ||
| Current concepts in the diagnosis and treatment of typhoid fever | Q34568917 | ||
| Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity | Q37150030 | ||
| Typhoid fever in children aged less than 5 years | Q39517030 | ||
| A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results | Q39568025 | ||
| Efficacy of a locally produced, Chinese Vi polysaccharide typhoid fever vaccine during six years of follow-up. | Q40501294 | ||
| Typhoid fever in Bangladesh: implications for vaccination policy | Q40602535 | ||
| Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine | Q40632057 | ||
| Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization | Q40670167 | ||
| Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines | Q40706749 | ||
| Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial | Q40757649 | ||
| Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee | Q40765461 | ||
| Protective activity of Vi capsular polysaccharide vaccine against typhoid fever | Q40792174 | ||
| Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report | Q40792921 | ||
| Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation | Q40797037 | ||
| Persistent Efficacy of Vi Conjugate Vaccine against Typhoid Fever in Young Children | Q50102582 | ||
| Safety and immunogenicity of Salmonella typhi Ty21a liquid formulation vaccine in 4- to 6-year-old Thai children | Q50174133 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | typhoid fever | Q83319 |
| systematic review | Q1504425 | ||
| meta-analysis | Q815382 | ||
| P304 | page(s) | 7848-7857 | |
| P577 | publication date | 2007-09-04 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials | |
| P478 | volume | 25 |
| Q40133170 | A Japanese study to assess immunogenicity and safety of a typhoid Vi polysaccharide vaccine |
| Q40372439 | A fall in Ghana. |
| Q40057417 | A novel approach for construction of an inactivated typhoid vaccine candidate that effectively augments both humoral and cellular immune responses |
| Q38715456 | A novel method to generate Salmonella Typhi Ty21a ghosts exploiting the λ phage holin-endolysin system |
| Q36820628 | A one-step homogeneous sandwich immunosensor for Salmonella detection based on magnetic nanoparticles (MNPs) and quantum Dots (QDs). |
| Q92438514 | A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever |
| Q52597561 | A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. |
| Q28088491 | A review of typhoid fever transmission dynamic models and economic evaluations of vaccination |
| Q34602404 | An adhesion protein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development |
| Q35798947 | Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. |
| Q38310237 | Antibodies and protection against invasive salmonella disease |
| Q39744171 | Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi |
| Q37679436 | Antigen targeting to M cells for enhancing the efficacy of mucosal vaccines |
| Q34425515 | B cells as a critical node in the microbiota-host immune system network |
| Q57941639 | Barriers to typhoid fever vaccine access in endemic countries |
| Q24621347 | Combined high-resolution genotyping and geospatial analysis reveals modes of endemic urban typhoid fever transmission |
| Q49998986 | Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study |
| Q40151178 | Construction of an attenuated Salmonella enterica serovar Paratyphi A vaccine strain harboring defined mutations in htrA and yncD. |
| Q37088080 | Contaminated water delivery as a simple and effective method of experimental Salmonella infection |
| Q36456788 | Cutting edge: B cells are essential for protective immunity against Salmonella independent of antibody secretion. |
| Q38408278 | Desirability for a typhoid fever vaccine among rural residents, Pemba Island, Tanzania |
| Q28394220 | Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide |
| Q36145803 | Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery |
| Q33855197 | Development of protective immunity to Salmonella, a mucosal pathogen with a systemic agenda |
| Q50005435 | Dietary supplementation with white button mushrooms augments the protective immune response to Salmonella vaccine in mice |
| Q36238036 | Differential diagnosis of illness in travelers arriving from Sierra Leone, Liberia, or Guinea: a cross-sectional study from the GeoSentinel Surveillance Network |
| Q35071000 | Direct visualization of endogenous Salmonella-specific B cells reveals a marked delay in clonal expansion and germinal center development |
| Q38678152 | Dual Immunization with SseB/Flagellin Provides Enhanced Protection against Salmonella Infection Mediated by Circulating Memory Cells. |
| Q34669382 | Early eradication of persistent Salmonella infection primes antibody-mediated protective immunity to recurrent infection. |
| Q90533031 | Effective mucosal live attenuated Salmonella vaccine by deleting phosphotransferase system component genes ptsI and crr |
| Q36159616 | Effectiveness of typhoid vaccination in US travelers |
| Q35344179 | Enteric fever in two vaccinated travellers to Latin America |
| Q26746887 | Entirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune Responses |
| Q34442222 | Flagella overexpression attenuates Salmonella pathogenesis |
| Q38537340 | Genetic susceptibility to invasive Salmonella disease |
| Q36509587 | Haloarchaeal gas vesicle nanoparticles displaying Salmonella SopB antigen reduce bacterial burden when administered with live attenuated bacteria |
| Q34515009 | Haloarchaeal gas vesicle nanoparticles displaying Salmonella antigens as a novel approach to vaccine development |
| Q34673466 | Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial |
| Q34150129 | High-resolution genotyping of the endemic Salmonella Typhi population during a Vi (typhoid) vaccination trial in Kolkata. |
| Q30155098 | Identification and characterization of OmpL as a potential vaccine candidate for immune-protection against salmonellosis in mice |
| Q30424877 | Identification of a common immune signature in murine and human systemic Salmonellosis |
| Q35882563 | Identifying an immune signature against invasive Salmonella |
| Q38059916 | Immune responses and protection in children in developing countries induced by oral vaccines |
| Q36743817 | Immunogenicity and Cross-Protective Efficacy Induced by Outer Membrane Proteins from Salmonella Typhimurium Mutants with Truncated LPS in Mice |
| Q40365149 | In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units |
| Q47564697 | In vivo tropism of Salmonella Typhi toxin to cells expressing a multiantennal glycan receptor. |
| Q90225914 | Instrument-Free and Visual Detection of Salmonella Based on Magnetic Nanoparticles and an Antibody Probe Immunosensor |
| Q37374692 | Kinetics of the natural, humoral immune response to Salmonella enterica serovar Typhi in Kathmandu, Nepal |
| Q36518258 | MHC class-I-restricted CD8 T cells play a protective role during primary Salmonella infection. |
| Q40203647 | New aspects in travel vaccinations |
| Q37846865 | Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection |
| Q33690625 | Overview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif®) |
| Q35626884 | Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events |
| Q40293025 | Preparation and evaluation of immunogenic conjugates of Salmonella enterica serovar Typhi O-specific polysaccharides with diphtheria toxoid |
| Q40107571 | Preventing invasive salmonellosis in children through vaccination |
| Q43421493 | Re: typhoid fever vaccines: systematic review and meta-analysis of randomised clinical trials |
| Q28308143 | Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas |
| Q37287154 | Salmonella Infection Enhances Erythropoietin Production by the Kidney and Liver, Which Correlates with Elevated Bacterial Burdens |
| Q30427484 | Salmonella Typhi OmpS1 and OmpS2 porins are potent protective immunogens with adjuvant properties. |
| Q28082931 | Salmonella as a model for non-cognate Th1 cell stimulation |
| Q37504399 | Salmonella enterica serovar Typhimurium mutants completely lacking the F(0)F(1) ATPase are novel live attenuated vaccine strains |
| Q50042606 | Soluble flagellin, FliC, induces an Ag-specific Th2 response, yet promotes T-bet-regulated Th1 clearance of Salmonella typhimurium infection. |
| Q47840879 | SopB of Salmonella enterica serovar Typhimurium is a potential DNA vaccine candidate in conjugation with live attenuated bacteria |
| Q40181057 | Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly |
| Q36708987 | The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen |
| Q40396446 | The expanding spectrum of disease due to salmonella: an international perspective |
| Q39775694 | Update on imminent vaccines: report of the APPA VU 2010: II. |
| Q39373957 | Vaccination against Salmonella Infection: the Mucosal Way. |
| Q37978121 | Vaccination against infection in patients with multiple sclerosis |
| Q39219003 | Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effector protein provides protection against lethal infection |
| Q28080866 | Vaccines against enteric infections for the developing world |
| Q27007088 | Vaccines against invasive Salmonella disease: current status and future directions |
| Q37608322 | Vaccines and biosimilarity: a solution or a problem? |
| Q57312007 | Vaccines for preventing typhoid fever |
| Q24201238 | Vaccines for preventing typhoid fever |
| Q34179527 | Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi |
| Q57946303 | Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic Design |
Search more.